GBT Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Global Blood Therapeutics (GBT) announced participation in two virtual investor conferences. The events include the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 at 2:30 p.m. ET and the Evercore ISI 3rd Annual HealthCONx on December 3 at 10:55 a.m. ET. Both fireside chats will be streamed live on GBT's website, with replays available for a month post-event. GBT is focused on developing treatments for sickle cell disease, having launched Oxbryta, the first FDA-approved treatment targeting the disease's root cause.

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:

• Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 at 2:30 p.m. ET;
• Evercore ISI 3rd Annual HealthCONx on December 3 at 10:55 a.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcast will be archived and available for one month following each event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Steven Immergut (investors and media)
650-410-3258
simmergut@gbt.com

 

FAQ

What investor conferences is GBT participating in during December 2020?

GBT is participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and the Evercore ISI 3rd Annual HealthCONx on December 3.

How can I watch GBT's investor conference presentations?

GBT's presentations will be webcast live on their website, with replays available for a month following each event.

What is the focus of Global Blood Therapeutics?

GBT is dedicated to developing treatments for sickle cell disease and has launched Oxbryta, the first FDA-approved treatment targeting sickle hemoglobin polymerization.

What treatments is GBT currently developing for sickle cell disease?

GBT is advancing inclacumab, a P-selectin inhibitor for pain crises, and GBT021601, a next-generation hemoglobin S polymerization inhibitor.